Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Tremblay

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Epilepsy & Behavior : E&B|February 26, 2017
Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic-clonic seizures in the United StatesGabriel Tremblay, Victoria Barghout, Vardhaman Patel, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 6, 2023
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United StatesLauren Ramjee, Nesrin Vurgun, Christopher Ngai, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 5, 2016
Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South KoreaGabriel Tremblay, Unnati Majethia, Janis L Breeze, et al.
Clinical Therapeutics|March 23, 2020
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United StatesGabriel Tremblay, Mike Dolph, Anuja Nidumolu Roy, et al.
Epilepsy & Behavior : E&B|July 14, 2018
Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspectiveGabriel Tremblay, Daniel Howard, Wan Tsong, et al.
Applied Health Economics and Health Policy|August 9, 2019
Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian SettingGabriel Tremblay, Ben Rousseau, Miriam Marquis, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Cancer Management and Research|June 5, 2018
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancerGabriel Tremblay, David Chandiwana, Mike Dolph, et al.
Breast Cancer (Dove Medical Press)|May 17, 2018
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancerAnna Forsythe, David Chandiwana, Janina Barth, et al.
JAMA Pediatrics|March 7, 2022
Humanistic and Economic Burden of Conversion Therapy Among LGBTQ Youths in the United StatesAnna Forsythe, Casey Pick, Gabriel Tremblay, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Epilepsy & Behavior : E&B|February 26, 2017
Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic-clonic seizures in the United StatesGabriel Tremblay, Victoria Barghout, Vardhaman Patel, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 6, 2023
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United StatesLauren Ramjee, Nesrin Vurgun, Christopher Ngai, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 5, 2016
Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South KoreaGabriel Tremblay, Unnati Majethia, Janis L Breeze, et al.
Clinical Therapeutics|March 23, 2020
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United StatesGabriel Tremblay, Mike Dolph, Anuja Nidumolu Roy, et al.
Epilepsy & Behavior : E&B|July 14, 2018
Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspectiveGabriel Tremblay, Daniel Howard, Wan Tsong, et al.
Applied Health Economics and Health Policy|August 9, 2019
Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian SettingGabriel Tremblay, Ben Rousseau, Miriam Marquis, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Cancer Management and Research|June 5, 2018
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancerGabriel Tremblay, David Chandiwana, Mike Dolph, et al.
Breast Cancer (Dove Medical Press)|May 17, 2018
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancerAnna Forsythe, David Chandiwana, Janina Barth, et al.
JAMA Pediatrics|March 7, 2022
Humanistic and Economic Burden of Conversion Therapy Among LGBTQ Youths in the United StatesAnna Forsythe, Casey Pick, Gabriel Tremblay, et al.
Pageof 6